一名代表團消息人士表示，俄羅斯認爲建立歐洲新安全框架是烏克蘭談判的主要重點。

Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed first‑participant dosing in an Australia Phase I/II study today. Preclinical data show strong inhibition in tumor cells and xenograft models with diverse RAS mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic, non‑small‑cell lung and colorectal cancers, and report favorable pharmacokinetics and safety.

China A-share physical-AI concept stocks were repeatedly active. Fulai New Materials hit the daily limit and extended to a record high; Fantuo Shuchuang, Hanwei Technology, Huayi Technology, Zhongkong Technology and Haitian Ruisheng each rose over 5%.